{
    "clinical_study": {
        "@rank": "73844", 
        "arm_group": [
            {
                "arm_group_label": "Drug: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin"
            }, 
            {
                "arm_group_label": "Drug:  vancomycin or  gentamicin", 
                "arm_group_type": "Experimental", 
                "description": "vancomycin 120 mg  every 8 hours or gentamicin 80 mg  every 8 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was :\n\n        -  to determine the effect of inhaled antibiotics on airway bacteria in ventilated\n           patients\n\n        -  to determine the effect of inhaled antibiotics on respiratory infection"
        }, 
        "brief_title": "Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit", 
        "completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Respiratory Infection", 
            "Bacterial Resistance", 
            "Respiratory Failure"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Tract Infections", 
                "Respiratory Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Double-blind randomized placebo controlled study examining the effect of aerosolized\n      antibiotics on respiratory infection signs and symptoms and on bacterial eradication and\n      resistance.\n\n      Systemic antibiotics are administered by the responsible physician"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  be on mechanical ventilation greater than 3 days\n\n          -  greater than or equal to 18 years and survival greater than 14 days\n\n          -  organisms on Gram stain with increasing purulent secretions\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  allergy to drugs administered"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878643", 
            "org_study_id": "20033799"
        }, 
        "intervention": [
            {
                "arm_group_label": "Drug:  vancomycin or  gentamicin", 
                "description": "Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours", 
                "intervention_name": "vancomycin or gentamicin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "gentamicin sulfate", 
                    "vancomycin hydrocloride"
                ]
            }, 
            {
                "arm_group_label": "Drug: Placebo", 
                "description": "normal saline administered to patient via nebulization", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline  2mL"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Gentamicins", 
                "Vancomycin", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "aerosolized antibiotic", 
            "ventilator-associated pneumonia", 
            "bacterial resistance", 
            "ventilator -associated tracheobronchitis", 
            "clinical pulmonary infection score"
        ], 
        "lastchanged_date": "June 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "STony Brook", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11794"
                }, 
                "name": "University Hospital Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study of the Effects of Inhaled Antibiotic on Bacterial Resistance", 
        "overall_official": {
            "affiliation": "Stony Brook University", 
            "last_name": "Lucy B Palmer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Tracheal aspirates are taken at randomization. Randomization to drug is determined by the Gram stain(organisms are Gram-positive, Gram-negative or both).  End of treatment culture, susceptibility and Gram stain of tracheal aspirate is taken after 14 days of treatment or at time of extubation, (which ever comes first).\nEradication is defined as absence of growth in culture and absence of organisms on Gram stain.", 
            "measure": "Eradication of multi-drug resistant bacteria", 
            "safety_issue": "Yes", 
            "time_frame": "Randomization and at end of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878643"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "CPIS is an index for risk of respiratory infection using a number of signs and symptoms . An index of greater than or equal to 6  suggests pneumonia", 
            "measure": "Clinical Pulmonary Infection Score (CPIS)", 
            "safety_issue": "No", 
            "time_frame": "Randomization and at end of treatment  which is defined as 14 days or at time of extubation, which ever comes first."
        }, 
        "source": "Stony Brook University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stony Brook University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}